Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
Public ClinicalTrials.gov record NCT00068692. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil
Study identification
- NCT ID
- NCT00068692
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 225 participants
Conditions and interventions
Conditions
- Rectal Mucinous Adenocarcinoma
- Rectal Signet Ring Cell Adenocarcinoma
- Recurrent Rectal Carcinoma
- Stage IIA Rectal Cancer AJCC v7
- Stage IIB Rectal Cancer AJCC v7
- Stage IIC Rectal Cancer AJCC v7
- Stage IIIA Rectal Cancer AJCC v7
- Stage IIIB Rectal Cancer AJCC v7
- Stage IIIC Rectal Cancer AJCC v7
- Stage IVA Rectal Cancer AJCC v7
- Stage IVB Rectal Cancer AJCC v7
Interventions
- Fluorouracil Drug
- Irinotecan Drug
- Leucovorin Calcium Drug
- Oxaliplatin Drug
- Radiotherapy Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 14, 2003
- Primary completion
- Nov 14, 2016
- Completion
- Nov 14, 2016
- Last update posted
- Dec 3, 2018
2003 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Eastern Cooperative Oncology Group | Boston | Massachusetts | 02215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00068692, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2018 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00068692 live on ClinicalTrials.gov.